Please ensure Javascript is enabled for purposes of website accessibility

Thermo Fisher Scientific to Produce Millions of COVID-19 Test Kits in the Next Few Weeks

By Cory Renauer - Updated Mar 16, 2020 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The world's leading manufacturer of scientific tools aims to rapidly address the shortage of coronavirus diagnostic kits in the U.S.

America's capacity to detect the coronavirus responsible for COVID-19 will get an enormous bump from Thermo Fisher Scientific (TMO -1.45%). The world's largest producer of scientific tools says it expects to have produced up to 5 million testing kits by the week of April 3.   

On Friday, the Food and Drug Administration granted emergency use authorization to COVID-19 testing kits from Thermo Fisher Scientific, Roche (RHHBY -2.04%), and a slew of their peers.

Covid-19 blood sample

Image source: Getty Images.

One piece of the puzzle

The number of test kits should soon meet the demand, but that alone won't unwind an enormous coronavirus testing backlog. Healthcare providers also need access to an Applied Biosystems 7500 Fast Dx Real-time PCR instrument and around four hours to gets results from a sample.

Laboratories all over the world already have instruments that can run Thermo Fisher's COVID-19 test kits, but each can only test so many samples at a time. According to the American Enterprise Institute, there are enough machines in the U.S. to run around 26,000 tests per day.  

Not a rainmaker

Investors who expect that the companies involved in COVID-19 testing will earn a swift windfall could be disappointed. Even assuming that roughly half of America's COVID-19 testing capacity gets directed to Thermo Fisher tests, it would still take over a year to work through 5 million kits. 

In 2019, Thermo Fisher recorded a whopping $25.5 billion in sales of instruments and services. Specialty diagnostics is an important part of the company's long-term growth strategy, but the entire operating segment was responsible for just 15% of its total revenue last year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$535.77 (-1.45%) $-7.87
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.36 (-2.04%) $0.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.